Want to see BAYRY full AI Analyst Report?
BAYRY Stock Chart & Stats
$11.02
-$0.08(-1.46%)
At close: 4:00 PM EST
$11.02
-$0.08(-1.46%)
Day’s Range― - ―
52-Week Range$7.26 - $15.27
Previous CloseN/A
Volume306.92K
Average Volume (3M)166.33K
Market Cap
$54.44B
Enterprise Value$82.92K
Total Cash (Recent Filing)$6.66B
Total Debt (Recent Filing)$38.93B
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 04, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend Yield0.23%
Share Statistics
EPS (TTM)-0.53
Shares Outstanding3,929,696,000
10 Day Avg. Volume197,199
30 Day Avg. Volume166,328
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.40
Price to Sales (P/S)0.83
P/FCF Ratio18.08
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$15.80Price Target Upside43.38% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)1.26
Revenue Forecast (FY)$52.39B
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Positive Cash FlowSustained ~59% gross margins and positive operating and free cash flow indicate durable product economics and manufacturing scale. Even with headline losses, recurring cash generation supports R&D, commercial investment and operational continuity over the next several quarters.
Expanded Clinical Trial PartnershipsNew alliances that expand trial infrastructure and patient access reduce recruitment timelines and development risk. Stronger trial throughput and academic partnerships can materially increase pipeline productivity and speed to market for new drugs over a multi-quarter horizon.
EUR 3B Strategic Equity Financing With ApolloA structured EUR 3B capital injection improves liquidity and eases near-term bond and litigation financing pressure while preserving operational control. This materially boosts financial flexibility and reduces refinancing risk during upcoming maturities.
Bears Say
Multi-year Revenue Decline & Negative Net IncomeA sustained top-line decline and continued net losses signal structural demand or product lifecycle challenges. This weakens reinvestment capacity, pressures margins over time, and makes future recovery hinge on successful new launches or turnaround in key segments.
Elevated LeverageHigher leverage limits strategic options and raises refinancing risk, especially with negative profitability. Elevated debt amplifies sensitivity to market and litigation shocks and constrains M&A, capex or aggressive R&D spending in the medium term.
Weakening Free Cash Flow & Poor Cash ConversionA declining FCF trend and low cash conversion limit internal funding for R&D, settlements or operational investments. Dependence on external financing may rise, increasing dilution or borrowing costs and elevating execution risk over the coming quarters.
Bayer News
BAYRY FAQ
What was Bayer AG’s price range in the past 12 months?
Bayer AG lowest stock price was $7.26 and its highest was $15.27 in the past 12 months.
What is Bayer AG’s market cap?
Bayer AG’s market cap is $54.44B.
When is Bayer AG’s upcoming earnings report date?
Bayer AG’s upcoming earnings report date is Aug 04, 2026 which is in 14 days.
How were Bayer AG’s earnings last quarter?
Bayer AG released its earnings results on May 12, 2026. The company reported $0.795 earnings per share for the quarter, beating the consensus estimate of $0.676 by $0.119.
Is Bayer AG overvalued?
According to Wall Street analysts Bayer AG’s price is currently Undervalued.
Does Bayer AG pay dividends?
Bayer AG pays a Annually dividend of $0.032 which represents an annual dividend yield of 0.23%. See more information on Bayer AG dividends here
What is Bayer AG’s EPS estimate?
Bayer AG’s EPS estimate is 0.22.
How many shares outstanding does Bayer AG have?
Bayer AG has 3,929,696,000 shares outstanding.
What happened to Bayer AG’s price movement after its last earnings report?
Bayer AG reported an EPS of $0.795 in its last earnings report, beating expectations of $0.676. Following the earnings report the stock price went up 3.278%.
Which hedge fund is a major shareholder of Bayer AG?
Currently, no hedge funds are holding shares in BAYRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bayer Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$15.80 (43.38% Upside)
$15.80 (43.38% Upside)
Blogger Sentiment
Bullish
BAYRY Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 240.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 2.9%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
71.40%
12-Months-Change
Fundamentals
Return on Equity
0.23%
Trailing 12-Months
Asset Growth
5.46%
Trailing 12-Months
Company Description
Bayer AG
Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.
BAYRY Stock 12 Month Forecast
Average Price Target
$15.80
▲(43.38% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.17% Mutual Funds
<0.01% Other Institutional Investors
99.83% Public Companies and
Individual Investors